ATOSSA THERAPEUTICS, INC. Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price
ATOSSA THERAPEUTICS, INC. (ATOS) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price of $0.00 per share for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-07.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice · last filed 2026-08-07
- ATOSSA THERAPEUTICS, INC. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for the quarter ending 2023-03-31 was $0.00.
- ATOSSA THERAPEUTICS, INC. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for the quarter ending 2021-09-30 was $2.46, a 2.50% increase year-over-year.
- ATOSSA THERAPEUTICS, INC. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for the quarter ending 2020-09-30 was $2.40.
- ATOSSA THERAPEUTICS, INC. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for the quarter ending 2015-03-31 was $0.00.
- ATOSSA THERAPEUTICS, INC. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for fiscal 2024 was $0.79.
- ATOSSA THERAPEUTICS, INC. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for fiscal 2021 was $2.46, a 2.50% increase from fiscal 2020.
- ATOSSA THERAPEUTICS, INC. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for fiscal 2020 was $2.40.
- ATOSSA THERAPEUTICS, INC. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for fiscal 2014 was $1.25, a 30.17% decline from fiscal 2013.
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 12 month |
|---|---|---|---|---|
| 2026-06-30 | $0.00 10-Q · filed 2026-08-07 | |||
| 2025-09-30 | $0.00 10-Q · filed 2025-11-12 | |||
| 2025-06-30 | $0.00 10-Q · filed 2025-08-12 | |||
| 2024-12-31 | $0.79 10-K · filed 2025-03-25 | |||
| 2024-09-30 | $0.79 10-Q · filed 2024-11-12 | |||
| 2024-06-30 | $0.85 10-Q · filed 2024-08-12 | |||
| 2023-09-30 | $0.00 10-Q · filed 2023-11-13 | |||
| 2023-06-30 | $0.00 10-Q · filed 2023-08-14 | |||
| 2023-03-31 | $0.00 10-Q · filed 2023-05-15 | |||
| 2021-12-31 | $2.46 10-K · filed 2022-02-28 | |||
| 2021-09-30 | $2.46 10-Q · filed 2021-11-15 | $2.46 10-Q · filed 2021-11-15 | ||
| 2021-06-30 | $0.00 10-Q · filed 2021-08-13 | |||
| 2020-12-31 | $2.40 10-K · filed 2021-03-31 | |||
| 2020-09-30 | $2.40 10-Q · filed 2021-11-15 | $2.40 10-Q · filed 2021-11-15 | ||
| 2015-09-30 | $0.00 10-Q · filed 2015-11-12 | |||
| 2015-06-30 | $0.00 10-Q · filed 2015-08-06 | |||
| 2015-03-31 | $0.00 10-Q · filed 2015-05-13 | |||
| 2014-12-31 | $1.25 10-K · filed 2015-03-30 | |||
| 2014-09-30 | $1.20 10-Q · filed 2014-11-12 | |||
| 2014-06-30 | $1.25 10-Q · filed 2014-08-12 | |||
| 2014-03-31 | $0.00 10-Q · filed 2014-05-14 | |||
| 2013-12-31 | $1.79 10-K · filed 2014-03-27 | |||
| 2013-09-30 | $1.79 10-Q · filed 2013-11-12 | |||
| 2013-06-30 | $1.79 10-Q · filed 2013-08-14 | |||
| 2013-03-31 | $1.25 10-Q · filed 2013-05-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cocrystal Pharma, Inc. (COCP) | United States | $0.022B | |
| Neuphoria Therapeutics Inc. (NEUP) | United States | $0.020B | -1.77 |
| Marker Therapeutics, Inc. (MRKR) | United States | $0.020B | -2.86 |
| Cellectar Biosciences, Inc. (CLRB) | United States | $0.020B | -1.03 |
| Shuttle Pharmaceuticals Holdings, Inc. (SHPH) | United States | $0.019B | -0.31 |
| ARTELO BIOSCIENCES, INC. (ARTL) | United States | $0.023B | |
| Rocket One Inc. (RKTO) | United States | $0.019B | |
| TherapeuticsMD, Inc. (TXMD) | United States | $0.024B | -117.87 |
| NextCure, Inc. (NXTC) | United States | $0.024B | -0.15 |
| Biofrontera Inc. (BFRI) | United States | $0.018B | -2.13 |